Embla Medical hf (OCSE:EMBLA)
kr 28.8 -0.3 (-1.03%) Market Cap: 12.30 Bil Enterprise Value: 15.63 Bil PE Ratio: 30.97 PB Ratio: 2.45 GF Score: 77/100

Preliminary Q2 2022 Ossur hf Earnings Call Transcript

Jul 18, 2022 / 01:00PM GMT
Release Date Price: kr29.6
Sveinn Solvason;ssur hf.;President;CEO
Ã

&

Thank you very much. I would like to welcome you to this conference call where we will begin by going through our revised guidance for 2022 and then sort of a brief overview of our preliminary results for quarter 2. And then we can go into a Q&A session afterwards.

Our revised organic growth guidance for 2022 is now 4% to 6%, previously 6% to 9% for the full year. And our revised guidance for EBITDA margin before special items is now 18% to 20% for 2022, adjusted from our previous estimate of 20% to 21%. Currently, we estimate that organic sales growth and EBITDA margin before special items will be around the middle of this new guidance range, and other guidance parameters are unchanged.

Now although sales have been strong in many key markets in EMEA and APAC in the first half of the year, sales have been slower than what we expected in Americas. COVID-19 related lockdowns in China have also impacted our sales in that important market. And then as we previously communicated, also sales to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot